-+ 0.00%
-+ 0.00%
-+ 0.00%

Sanofi says Japan approves Sarclisa subcutaneous formulation for multiple myeloma

PUBT·06/19/2026 10:31:32
Listen to the news
Sanofi says Japan approves Sarclisa subcutaneous formulation for multiple myeloma
  • Japan cleared Sanofi’s subcutaneous Sarclisa for multiple myeloma, covering relapsed or refractory disease and newly diagnosed patients.
  • Approval was supported by the Phase 3 IRAKLIA study showing non-inferior efficacy vs IV dosing, with ORR of 71.1% vs 70.5%.
  • Japan is reviewing the CirCLIQ on-body injector submission from Enable Injections for Sarclisa SC administration.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606190631PRIMZONEFULLFEED1001188646) on June 19, 2026, and is solely responsible for the information contained therein.